Structural Diversity and Stability of Hexamorphic Mavacamten: Experimental and Computational Insights

IF 3.4 2区 化学 Q2 CHEMISTRY, MULTIDISCIPLINARY
Doris E. Braun*, Marijan Stefinovic and Ulrich J. Griesser, 
{"title":"Structural Diversity and Stability of Hexamorphic Mavacamten: Experimental and Computational Insights","authors":"Doris E. Braun*,&nbsp;Marijan Stefinovic and Ulrich J. Griesser,&nbsp;","doi":"10.1021/acs.cgd.4c0088910.1021/acs.cgd.4c00889","DOIUrl":null,"url":null,"abstract":"<p >Mavacamten (MAV), an innovative therapeutic agent targeting hypertrophic cardiomyopathy, was found to crystallize in six polymorphs, three solvates, and also to form an amorphous phase. The compound crystallizes easily, but often concomitantly, with five out of the six structures of the polymorphs solved, allowing for unambiguous identification of the phases. Experimental and computational methods consistently indicate that the stability order at 0 K for three of the five structurally characterized polymorphs is <b>I</b> (most stable) &gt; <b>II</b> &gt; <b>IV</b>. For forms <b>III</b> and <b>V</b>, they disagree on which of the two is the least stable. The metastable forms, with the exception of <b>V</b>, show very high kinetic stability under ambient conditions. This contrasts with the unstable solvates (chloroform, pyridine, and <i>N</i>-methylpyrrolidone) and the amorphous phase, which readily transform into the anhydrates. Numerous feasible crystal structures were identified among the lowest-energy structures on the computationally generated lattice energy landscape. The calculations reveal that uniquely distinct MAV conformations can form the same type of strong H-bonded chain motif, which is a characteristic feature of the structures, rationalizing the stability of the metastable forms and their tendency to crystallize concomitantly. These findings emphasize the significance of computational tools in understanding and predicting the polymorphic behavior of complex pharmaceutical compounds. Furthermore, this study highlights the need for continued improvements of modeling tools to enhance their predictive accuracy and practical application.</p><p >Mavacamten crystallizes in six polymorphs with packing and conformational variability, three transient solvates, and an unstable amorphous phase. The exclusive formation of one very strong H-bonding motif in all experimental and nearly all computed low-energy structures explains the high tendency for concomitant crystallization and the high kinetic stability of the metastable forms. Computational tools were crucial for unraveling the solid-state behavior of mavacamten.</p>","PeriodicalId":34,"journal":{"name":"Crystal Growth & Design","volume":"24 20","pages":"8381–8396 8381–8396"},"PeriodicalIF":3.4000,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.acs.org/doi/epdf/10.1021/acs.cgd.4c00889","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Crystal Growth & Design","FirstCategoryId":"92","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.cgd.4c00889","RegionNum":2,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

Abstract

Mavacamten (MAV), an innovative therapeutic agent targeting hypertrophic cardiomyopathy, was found to crystallize in six polymorphs, three solvates, and also to form an amorphous phase. The compound crystallizes easily, but often concomitantly, with five out of the six structures of the polymorphs solved, allowing for unambiguous identification of the phases. Experimental and computational methods consistently indicate that the stability order at 0 K for three of the five structurally characterized polymorphs is I (most stable) > II > IV. For forms III and V, they disagree on which of the two is the least stable. The metastable forms, with the exception of V, show very high kinetic stability under ambient conditions. This contrasts with the unstable solvates (chloroform, pyridine, and N-methylpyrrolidone) and the amorphous phase, which readily transform into the anhydrates. Numerous feasible crystal structures were identified among the lowest-energy structures on the computationally generated lattice energy landscape. The calculations reveal that uniquely distinct MAV conformations can form the same type of strong H-bonded chain motif, which is a characteristic feature of the structures, rationalizing the stability of the metastable forms and their tendency to crystallize concomitantly. These findings emphasize the significance of computational tools in understanding and predicting the polymorphic behavior of complex pharmaceutical compounds. Furthermore, this study highlights the need for continued improvements of modeling tools to enhance their predictive accuracy and practical application.

Mavacamten crystallizes in six polymorphs with packing and conformational variability, three transient solvates, and an unstable amorphous phase. The exclusive formation of one very strong H-bonding motif in all experimental and nearly all computed low-energy structures explains the high tendency for concomitant crystallization and the high kinetic stability of the metastable forms. Computational tools were crucial for unraveling the solid-state behavior of mavacamten.

六形态岩浆岩的结构多样性和稳定性:实验和计算的启示
研究发现,Mavacamten(MAV)是一种针对肥厚型心肌病的创新性治疗药物,它能以六种多晶型、三种溶解物和一种无定形相结晶。该化合物很容易结晶,而且经常同时结晶,在六种多晶体结构中,有五种结构已经解决,从而可以明确地确定各相。实验和计算方法一致表明,五种结构表征的多晶型中有三种在 0 K 时的稳定性顺序为 I(最稳定)> II >IV。对于形态 III 和 V,他们在哪种形态最不稳定的问题上存在分歧。在环境条件下,除 V 外,其他可蜕变形态都表现出极高的动力学稳定性。这与不稳定的溶解物(氯仿、吡啶和 N-甲基吡咯烷酮)和无定形相形成鲜明对比,无定形相很容易转化为无水物。在计算生成的晶格能谱上的最低能量结构中,确定了许多可行的晶体结构。计算结果表明,独特的 MAV 构象可以形成相同类型的强 H 键链图案,这是这些结构的一个特征,从而合理解释了蜕变形式的稳定性及其同时结晶的趋势。这些发现强调了计算工具在理解和预测复杂药物化合物多态性方面的重要意义。此外,这项研究还强调了继续改进建模工具以提高其预测准确性和实际应用的必要性。Mavacamten 会结晶成六种具有堆积和构象变异性的多晶型、三种瞬时可溶物和一种不稳定的无定形相。在所有实验结构和几乎所有计算出的低能结构中,只形成了一个非常强的氢键基团,这说明了同时结晶的高倾向性和蜕变形式的高动力学稳定性。计算工具对于揭示 mavacamten 的固态行为至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Crystal Growth & Design
Crystal Growth & Design 化学-材料科学:综合
CiteScore
6.30
自引率
10.50%
发文量
650
审稿时长
1.9 months
期刊介绍: The aim of Crystal Growth & Design is to stimulate crossfertilization of knowledge among scientists and engineers working in the fields of crystal growth, crystal engineering, and the industrial application of crystalline materials. Crystal Growth & Design publishes theoretical and experimental studies of the physical, chemical, and biological phenomena and processes related to the design, growth, and application of crystalline materials. Synergistic approaches originating from different disciplines and technologies and integrating the fields of crystal growth, crystal engineering, intermolecular interactions, and industrial application are encouraged.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信